



Research & Innovation 2018

New Biology, New Targets

Homerton College, Cambridge
17th -18th April 2018



#ELRIGRI18

www.elrig.org

We are very pleased to welcome you to ELRIG's 6th Annual Research & Innovation conference which for the second time is being held in Cambridge. We are delighted to be hosting this meeting in this global centre of excellence in research and innovation.

This ELRIG event is intended to capture and present emerging opportunities in drug discovery research, often as they first arise in the academic arena. Our theme for this year's conference is "New Biology, New Targets" and under this umbrella we have put together themed tracks exploring the innovations driving the identification and prosecution of novel targets. We also have specific tracks focussed on emerging targets in two of the highest priority areas of medical need, namely oncology and neuroscience.

Complementing the excellent presentations in these tracks we are honoured to be joined by our two plenary keynote speakers, Tony Kouzarides (Gurdon Institute and Milner Therapeutics Institute) and Iain Chessell (IMED Head of Neuroscience at AstraZeneca) who will share their perspectives on the future direction of oncology and neuroscience drug discovery from the leading edge of academic and industrial research.

DAY 1: TUESDAY 17TH APRIL

	THE AUDITORIUM	THE BOULIND SUITE
	TECHNOLOGIES & STRATEGIES FOR NOVEL TARGET DISCOVERY	NOVEL TARGETS IN ONCOLOGY
8:00 - 9:15	REGISTRATION & COFFEE	
9:15 - 9:30	AUDITORIUM: Conference Directors' Welcome & introduction to Plenary Keynote Mark Wigglesworth (Astrazeneca) & Mike Kerins (Cambridge Bioscience)	
9:30 - 10:15	AUDITORIUM: PLENARY KEYNOTE Making a difference to therapy through science Professor Tony Kouzarides (Gurdon Institute and Milner Therapeutics Institute)	
10:15 - 10:50	COFFEE	
10:50 - 11:00	Session chairs introductions: Ian Dunham (Sanger Open Targets) & Michael Dabrowski (Pelago Bioscience)	Session chairs introductions: James Lynch (AstraZeneca) & Neil Jones (Cancer Research UK)
11:00 - 11:30	Single cell RNA sequencing - a vehicle to target discovery Menna Clatworthy (Cambridge Clinical School)	The role of dysregulated RNA splicing in colorectal tumourigenesis Kevin Myant (Cancer Research UK Edinburgh Centre)
11:30 - 11:35	Vendor Spotlight: Anna Groom (LabLogic Systems Ltd)	Vendor Spotlight: Charlotte Egan (Miltenyi Biotec Ltd)
11:35 - 11:40	Vendor Spotlight: Peter Djali (Formulatrix, Inc)	Vendor Spotlight:
11:40 - 12:10	Catalysing the production of more novel high quality inhibitors, to de-risk new targets for drug discovery Chas Bountra (SGC, Oxford University)	STING activation can overcome tumour-mediated resistance to antibody immunotherapy Stephen Beers (University of Southampton)
12:10 - 12:15	Vendor Spotlight: Dora Quest (LGC)	Vendor Spotlight:
12:15 - 12:20	Vendor Spotlight: Nirmal Perera (LGC-ATCC)	Vendor Spotlight:
12:20 - 13:20	LUNCH - EXHIBITION - POSTERS	
13:20 - 13:50	Applying AI to produce new insights in drug discovery & development Ian Churcher (BenevolentAI)	Heating up the tumour with innate immune agonists Stefanie Mullins (Medimmune)
13:50 - 14:20	Poster Spotlight Presentations: Joanne Yarker (Phoremest) Imbisaat Geti (Elpis BioMed)	Poster Spotlight Presentations: Afshan Ahmed (AstraZeneca) Miniver Oliver (Essen Bioscience)
14:20 - 14:50	Target Identification via Genome-wide CRISPR-Cas9 Screens in Human Cancer Cell Lines Fiona Behan (Sanger Institute)	Novel strategies to delay or overcome acquired resistance to drugs targeting the ERK1/2 pathway Simon Cook (The Babraham Institute)
14:50 - 14:55	Vendor Spotlight:	Vendor Spotlight:
14:55 - 15:00	Vendor Spotlight: Bernadett Kolozsvari (Sartorius Stedim Biotech)	Vendor Spotlight:
15:00 - 15:30	COFFEE	
15:30 - 16:00	MS-CETSA for target deconvolution at different stages of drug discovery Nayana Prabhu (Nanyang Technological University)	AZD4785 a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS Sarah Ross (AstraZeneca)
16:00 - 16:30	Discovery and development of positive allosteric modulators of neurotrophin signaling Pontus Forsell (Alzecure Pharma AB)	Targeting Wnt signalling in colorectal cancer Vivian Li (The Francis Crick Institute)
16:30 - 17:00	Precision systems medicine from leukemia to solid tumors Päivi Östling (Science for Life Laboratory, Dept. of Oncology & Pathology, Karolinska Institutet)	Phage to Phase 1:- Development of the bicycle toxin conjugate BT1718 Mike Rigby (Bicycle Therapeutics)
17:00 - 19:00	NETWORKING - DRINKS RECEPTION - WINE TASTING	

The planning and organisation of this meeting was due to the efforts of many individuals. In particular, we would like to thank our session chairs: Ian Dunham (Sanger Open Targets) & Michael Dabrowski (Pelago Bioscience), James Lynch (AstraZeneca) & Neil Jones (Cancer Research UK), Friedrich Reinhard (Cellzome) & Markus Muellner (Phoremest), Carol Routledge (ARUK) & Stephen Sawcer (Cambridge Neuroscience) for their hard work and dedication in putting together an exciting and impressive scientific programme. We would also like to thank the ELRIG team for their support.

ELRIG is a leading European not-for-profit organization that exists to provide outstanding scientific content to the life science community and a platform where academic and industry thought leaders come together to network and promote new innovations in drug discovery. ELRIG is particularly proud to provide free delegate attendance at the conference, which would not be possible without the generous support of the sponsors and exhibitors.

We hope that you all enjoy the meeting and use it as an opportunity to network with friends, make new contacts and discuss new and interesting scientific advances and their ability to impact early drug discovery.

Mark Wigglesworth

(Director, High Throughput Screening, AstraZeneca)

Mike Kerins

(Managing Director, Cambridge Bioscience)

DAY 2: WEDNESDAY 18TH APRIL

	THE AUDITORIUM	THE BOULIND SUITE
	TECHNOLOGIES FOR NOVEL TARGET PROSECUTION	TARGETS IN NEUROSCIENCE
8:00 - 9:00	REGISTRATION & COFFEE	
9:00 - 9:10	Session chairs introductions: Friedrich Reinhard (Cellzome) & Markus Muellner (Phoremest)	Session chairs introductions: Carol Routledge (ARUK) & Stephen Sawcer (Cambridge Neuroscience)
9:10 - 9:40	Application of AI and Centaur intelligence in drug discovery Jérémy Besnard (Exscientia)	Novel targets to promote repair in multiple sclerosis Alasdair Coles (University of Cambridge)
9:40 - 9:45	Vendor Spotlight: Craig Malcolm (Promega UK Ltd)	Vendor Spotlight: Zoe Nilsson (Axol Bioscience Ltd)
9:45 - 9:50	Vendor Spotlight:	Vendor Spotlight:
9:50 - 10:20	Target Validation with Chemical Probes Kilian Huber (SGC)	Targeting neurodegeneration: the Astex approach Lee Dawson (Astex Pharmaceuticals)
10:20 - 10:25	Vendor Spotlight: Michael Dabrowski (Pelago Bioscience AB)	Vendor Spotlight: Meera Swami (LifeArc)
10:25 - 10:30	Vendor Spotlight:	Vendor Spotlight: Antoine Fouillet (BioTek Instruments Ltd)
10:30 - 11:00	COFFEE	
11:00 - 11:30	soloMER Biologics - naturally targeting cryptic epitopes Caroline Barelle (Elasmogen Ltd)	Targeting Dysregulated UPR Signalling for Neuroprotection Mark Halliday (University of Cambridge)
11:30 - 12:00	Poster Spotlight Presentations: Claudia Stellato (AstraZeneca)	Poster Spotlight Presentations: Lauren Hindhaugh (CENSO Biotechnologies) Meera Raja (Sygnature Discovery)
12:00 - 12:30	Title TBC Stephen Megit (Immunocore)	A multifaceted approach to disease mechanisms in common and rare forms of Parkinsonism George Tofaris (Nuffield Department of Clinical Neurosciences, University of Oxford)
12:30 - 12:35	Vendor Spotlight:	Vendor Spotlight: Louise Affleck (Cisbio)
12:35 - 12:40	Vendor Spotlight:	Vendor Spotlight:
12:40 - 13:50	LUNCH - EXHIBITION - POSTERS	
13:50 - 13:55	AUDITORIUM: Introduction to Plenary Keynote	
13:55 - 14:40	AUDITORIUM: PLENARY KEYNOTE From target to clinic: progress in neuroscience Iain Chessell (AstraZeneca)	
14:40 - 15:10	COFFEE	
15:10 - 15:40	Protein degradation using PROTACs as a novel drug discovery modality Gillian Watt (GlaxoSmithKline)	Stem Cell approaches to identify new targets and new therapies in Parkinson's Disease Caleb Webber (Henry Wellcome Centre for gene Function, Oxford University)
15:40 - 16:10	PROTACs: From chemical biology to drug discovery William Farnaby (University of Dundee)	Artificial Intelligence-Based Assessment of Cognitive Impairment in Neurodegenerative Diseases Sayed-Mahdi Khaligh-Razavi (Cognetivity Ltd)
16:10 - 16:40	The challenges of prosecuting RNA-modifying enzymes as drug discovery targets Dan Leggate (Storm Therapeutics Ltd)	Neurodegeneration at the interface between genomic instability and autophagy Sherif El-Khamisy (University of Sheffield)
16:40 - 17:00	CLOSING REMARKS & CONFERENCE CLOSE	

RESEARCH & INNOVATION 2018 GOLD SPONSORS



LCG Group
www.lcggroup.com/our-science/
genomics-solutions



LifeArc
www.lifearc.org



Merck
www.merckmillipore.com



Sartorius
www.tapbiosystems.com

RESEARCH & INNOVATION 2018 BRONZE SPONSORS



Axol Bioscience Ltd
www.axolbio.com



BioTek Instruments Ltd
www.biotek.com



Cisbio
www.cisbio.com



Formulatrix
www.formulatrix.com



Lablogic Systems Ltd
www.lablogic.com



LCG - ATCC
www.lgcstandards-atcc.org/



Miltényi Biotec
www.miltenyibiotec.com



Pelago Bioscience AB
www.pelagobio.com



Promega UK Ltd
www.promega.com



RD-Biotech
www.rd-biotech.com

RESEARCH & INNOVATION 2018 EXHIBITORS



Beckman Coulter Ltd UK
www.beckmancoulter.com



BlueCatBio GmbH
www.bluecatbio.com



BMG LABTECH Ltd
www.bmglabtech.com



Cambridge Bioscience
www.bioscience.co.uk



Gilson UK
www.gilsonuk.com



Greiner Bio One Ltd
www.gbo.com



Integra
www.integra-biosciences.com



MIP Diagnostics Limited
www.mip-dx.com



Peak Proteins
www.peakproteins.com



Tecan UK Ltd
www.tecan.com

RESEARCH & INNOVATION 2018 CAREER AND MEDIA PARTNERS



Biostrata
www.biostratamarketing.com



Drug Target Review
www.dugtargetreview.com



Langton Howarth
www.langtonhowarth.co.uk



Technology Networks
www.technologynetworks.com



UKSPA
www.ukspa.org.uk

CALLING ALL EARLY CAREER PROFESSIONALS



Are you a student, post doc, or in your first 5 years of employment in the biomedical sector? If so, ELRIG would love to hear your views on how we can further develop our meetings to meet your needs. Please take a moment to complete our survey, either online at www.menti.com using the code 79 78 25, or via the old school paper form you received from the ELRIG team. Two minutes of your time will really help us shape future meetings for you. Many thanks in advance!

UPCOMING ELRIG EVENTS



Discovery Technologies 2018
Mass Spectrometry & Organ on a Chip
Alderley Park, Cheshire
22nd - 23rd May 2018



Drug Discovery 2018
Drug Discovery for Small & Large Molecules
Excel Arena, London
9th - 10th October 2018



Pharmaceutical Flow Cytometry & Imaging 2018
From Single Cell to Patient
GlaxoSmithKline, Stevenage
14th - 15th November 2018

Make sure you are part of these events. Book your place NOW!
For more information please contact the ELRIG team:
E-mail: info@elrig.org Tel: +44 (0)7484 113971

www.elrig.org